MEDICENNA THERAPEUTICS
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines (ECs) for the treatment of a broad range of cancers. Its proprietary technology platform supports a unique, multi-methodology treatment paradigm that can precisely deliver potent cell-killing agents for cancer as well as actively alter the immunosuppressive tumor micro-environment without harming healthy cells. The company was founded in 2012 and based in Toronto, Ontario, Canada.
MEDICENNA THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics Wellness
Founded:
2012-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.medicenna.com
Total Employee:
11+
Status:
Active
Contact:
866-393-4891
Email Addresses:
[email protected]
Total Funding:
55.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical stage biotechnology company.
Current Employees Featured
Founder
Stock Details
Investors List
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Post-IPO Debt - Medicenna Therapeutics
Official Site Inspections
http://www.medicenna.com Semrush global rank: 3.7 M Semrush visits lastest month: 3.74 K
- Host name: 87.186.102.34.bc.googleusercontent.com
- IP address: 34.102.186.87
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Medicenna Therapeutics"
Home | Medicenna
Medicenna is a clinical stage immunotherapy company that uses directed evolution to generate engineered interleukins called Superkines that can modulate, fine-tune or amplify the immune …See details»
About - Medicenna
The Medicenna mission is to leverage our world-class cytokine biology expertise to design life-changing therapies that will transform people’s lives.See details»
Management Team | Investor Relations - Medicenna
View the management team for Medicenna Therapeutics.See details»
Medicenna Therapeutics Corp. - LinkedIn
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered …See details»
Medicenna Therapeutics - Crunchbase Company …
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines (ECs) for …See details»
Medicenna Presents Preclinical Data on MDNA11 and …
3 days ago · Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, …See details»
Medicenna Reports Fiscal Year 2023 Financial Results and …
Mar 31, 2023 · TORONTO and HOUSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical …See details»
Medicenna Reports Fiscal Year 2022 Financial Results and …
TORONTO and HOUSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage …See details»
Medicenna Reports Second Quarter Fiscal 2025 Financial …
Sep 30, 2024 · TORONTO and HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a …See details»
Clinical Trials - Medicenna
Medicenna recognizes that patient participation in clinical trials is critical to advance treatments for cancer. Learn about our ongoing and upcoming studies.See details»
Medicenna Announces Upcoming Presentations at the 29th …
Nov 13, 2024 · Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and …See details»
Medicenna gains precedent-setting FDA approval to design …
In a precedent-setting regulatory decision, the FDA agreed to consider the use of a hybrid SCA in Medicenna’s Phase 3 registrational trial. The hybrid SCA will reduce the number of …See details»
Platform - Medicenna
Medicenna focuses on creating its therapies using interleukins from three major families: IL-2, IL-4 and IL-13. These three families are known to modulate immune activity against 2000 different …See details»
Medicenna Therapeutics Corp. (MDNA.TO) - Yahoo …
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and …See details»
Medicenna Reports First Quarter Fiscal 2025 Financial …
Aug 1, 2024 · Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class …See details»
Medicenna To Present Evidence of Durable Single Agent
May 31, 2024 · MDNA11 shows significant increases in stemness, central and effector memory and markers of enhanced effector function in circulating CD8+ T and NK cells, all of which are …See details»
Medicenna Announces Clinical Collaboration with Merck to
Sep 13, 2022 · Under the terms of the clinical trial supply and collaboration agreement, Medicenna will sponsor the study and Merck will supply KEYTRUDA ®. The two companies …See details»
Board of Directors | About | Medicenna
Mr. Lalji joins Medicenna’s Board of Directors with broad governance experience, having served as Chairman of the Board for the oncology-focused Sitka Biopharma, and as Board Member of …See details»
Medicenna Provides Update on its Presentations at the …
TORONTO and HOUSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage …See details»
Medicenna Reports First Quarter Fiscal 2025 Financial …
TORONTO and HOUSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage …See details»